PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 39 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,000 | -99.2% | 13,721 | -96.9% | 0.00% | – |
| Q2 2022 | $264,000 | -31.4% | 439,265 | +50.4% | 0.00% | -100.0% |
| Q1 2022 | $385,000 | -48.5% | 291,998 | +2.0% | 0.00% | 0.0% |
| Q4 2021 | $747,000 | -18.0% | 286,259 | -2.2% | 0.00% | 0.0% |
| Q3 2021 | $911,000 | -6.8% | 292,840 | +11.5% | 0.00% | 0.0% |
| Q2 2021 | $977,000 | +14.8% | 262,693 | +6.8% | 0.00% | 0.0% |
| Q1 2021 | $851,000 | +20.5% | 245,887 | +17.0% | 0.00% | 0.0% |
| Q4 2020 | $706,000 | +7.1% | 210,125 | +11.9% | 0.00% | 0.0% |
| Q3 2020 | $659,000 | -19.1% | 187,837 | +6.0% | 0.00% | -50.0% |
| Q2 2020 | $815,000 | +44.0% | 177,186 | -0.4% | 0.00% | 0.0% |
| Q1 2020 | $566,000 | -42.3% | 177,868 | +9.1% | 0.00% | 0.0% |
| Q4 2019 | $981,000 | +16.2% | 163,043 | -19.9% | 0.00% | 0.0% |
| Q3 2019 | $844,000 | -11.3% | 203,458 | +178.9% | 0.00% | 0.0% |
| Q2 2019 | $951,000 | – | 72,961 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |